ALTSTATION.IO

Solventum Corporation (SOLV) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$77.67

Change

+0.89%

Market Cap

$13.47B

Avg Volume

1.1M

Company Overview

Solventum Corporation (SOLV) is a healthcare company headquartered in Maplewood, Minnesota. They develop, manufacture, and sell a range of medical instruments and supplies aimed at meeting critical needs in patient care. Their portfolio includes products for negative pressure wound therapy, advanced wound dressings, various surgical supplies, and dental solutions like brackets and aligners. Their Health Information Systems segment provides essential software for healthcare systems, focusing on documentation and coding automation. Solventum serves various customers, including hospitals, clinics, dental practices, and end consumers through multiple sales channels.

In terms of competitive positioning, Solventum is a challenger in the Medical Instruments & Supplies sector. They face competition from established names like Medtronic and 3M, which have extensive product lines and greater market share. Despite this, Solventum differentiates itself with innovative technology, particularly in their Health Information Systems, which helps improve workflow efficiency in healthcare settings. Their focus on quality and customer-centric solutions gives them an edge, but they must navigate pricing pressures and evolving regulatory demands.

Currently, Solventum is on a growth trajectory. Incorporated in 2023, they are building their market presence and expanding their product reach. Recent milestones include the launch of several new products in the Medsurg and Dental Solutions segments, aimed at filling gaps in current offerings. Their strategic focus is on innovation and market penetration, which is critical as they establish themselves in a competitive landscape.

Key Financials

Market Cap

$13.47B

Revenue

$8.40B

EBITDA

$1.26B

Gross Margin

54.4%

Profit Margin

18.1%

Revenue Growth

0.7%

Total Cash

$1.64B

Total Debt

$5.14B

Free Cash Flow

$587.75M

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

8.92

Forward P/E

12.24

Beta

N/A

52-Week High

$88.20

52-Week Low

$60.70

EPS

$8.71

50-Day Avg

$81.19

200-Day Avg

$74.76

Price/Book

2.70

Technical Analysis

The stock chart for Solventum Corporation (SOLV) exhibits a predominantly bullish trend over the 52-week period, with a modest increase of 5.1%, indicating some upward momentum. Key resistance is evident near the $78.12 level, which has been tested multiple times throughout the year but not decisively broken. Support is identified around the $70 level, where prices have consistently bounced back in previous dips. Notable price patterns include a sharp rise to approximately $86 in March followed by a significant correction, resulting in a volatile trading range in the subsequent months. Recently, the price has shown positive momentum, holding steady near $77.67, just slightly below the key resistance level. Currently, SOLV’s price is near the upper end of its 52-week range, which implies that a breakout above $78.12 could signal stronger upward moves, while failure to hold current levels may draw it back toward support at $70.

Recent News and Developments

Market Update

Here’s a summary of the latest news and developments for Solventum Corporation (SOLV) stock in the past week:

1. KeyCorp Adjusts EPS Estimate While Maintaining “Overweight” Rating

On February 6, 2026, KeyCorp analysts lowered their fiscal year 2026 earnings per share (EPS) estimate for Solventum Corporation to $6.20 from $6.30. Despite this revision, the firm maintained its “Overweight” rating and a price target of $97 for SOLV stock. This adjustment comes amidst a backdrop of mixed analyst sentiment, although the company has seen prior positive catalysts including earlier upgrades from KeyBanc, BTIG, and Stifel, and a board approval of a $1.0 billion share buyback program.

2. Diamond Hill Large Cap Fund Discloses New Position in Solventum

As of February 5, 2026, Diamond Hill Large Cap Fund announced a new position in Solventum Corporation. This move highlights the healthcare company’s standalone profile, refreshed leadership, and a strategic focus on revenue growth and product mix following its spin-off from 3M in April 2024. Analysts currently peg Solventum’s fair value at approximately $88.55 per share, suggesting a potential valuation gap compared to its recent closing price of $76.49.

Market Sentiment and Analyst Recommendations

Bull Case

Solventum trades at 8.92x earnings, which is cheap for a healthcare company with a $13.47B market cap and $8.4B in revenue. The 12-analyst consensus target is $89.25, implying 15% upside from current levels, with KeyCorp maintaining an Overweight rating and $97 price target despite trimming their EPS estimate. The company just spun off from 3M in April 2024 and is executing a $1B share buyback program, which will reduce share count and support EPS growth even if revenue stays flat. New product launches in dental (Clinpro Clear Fluoride and Filtek Easy Match) show the company is still innovating and expanding its addressable market. The stock is sitting right at $77.67, just below the $78.12 resistance level, and a breakout could trigger the move toward $88-97 that analysts are pricing in. Diamond Hill Large Cap Fund’s new position signals institutional confidence in the standalone story and refreshed leadership.

Bear Case

Revenue growth is essentially dead at 0.7%, which is a major red flag for a company that’s supposed to be in growth mode post-spin. The debt load of $5.14B against only $1.64B in cash leaves limited financial flexibility, especially if the company faces unexpected headwinds or needs to invest heavily to reignite growth. The stock has already rallied 5.1% over 52 weeks and is near the top of its range, meaning much of the good news may be priced in already. KeyCorp’s EPS estimate cut from $6.30 to $6.20, while they maintained their rating, suggests consensus expectations are softening and execution risks are real. The dental products being launched are incremental improvements, not transformative breakthroughs, which won’t move the needle on a $13.47B company. Solventum faces competition from larger diversified healthcare players with deeper pockets and better distribution, and the 0.7% revenue growth indicates it’s losing share or operating in flat markets.

What to Watch

The Q4 and full-year 2025 earnings report on February 26, 2026 is critical. Watch for revenue growth acceleration above 2-3% and whether management guides for improved growth in 2026, otherwise the bear case gets stronger. Monitor the EPS print against KeyCorp’s new $6.20 estimate for 2026 and any changes to full-year guidance that could signal momentum or deterioration. Track whether the company can execute its $1B buyback program on schedule, since this is a key driver of per-share earnings growth when organic revenue growth is weak. Watch the $78.12 resistance level closely over the next few weeks. A decisive break above it could confirm the uptrend toward $88-97, while a drop below $76 would suggest the stock is rolling over toward the $70 support level and the bear case is taking hold. Finally, monitor the dental product launches for early traction and whether they gain meaningful market adoption in 2026, since this is one of the few visible catalysts for organic growth.

Analyst Consensus

BUY

Based on 12 analyst opinions

Low Target

$71.00

Mean Target

$89.25

High Target

$105.00

Earnings and Financial Data

Sector

Healthcare

Industry

Medical Instruments & Supplies

Employees

22,000

Earnings & Dividends

Next Earnings

Feb 26, 2026

EPS (Trailing)

$8.71

Dividend Yield

None

Payout Ratio

Frequently Asked Questions

Is SOLV a good stock to buy?

Yes, SOLV has a strong P/E ratio of 8.92, indicating it’s undervalued compared to many peers. The analyst recommendation is a solid BUY, with a target price of $89.25, suggesting potential upside.

What is SOLV’s price target?

The current analyst price target for SOLV is $89.25. This target indicates about a 15% upside from the current price of $77.67.

Does SOLV pay a dividend?

No, Solventum Corporation does not currently pay a dividend. Investors looking for income from dividends will need to consider other options.

What is SOLV’s market cap?

Solventum Corporation has a market cap of $13.47 billion. This positions it as a significant player in the healthcare sector, particularly in medical instruments and supplies.

What is the range of SOLV’s stock price over the past year?

The 52-week price range for SOLV has been between $60.70 and $88.20. Currently trading near the upper end of this range may indicate strong investor confidence.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.